Postmarketing Pharmaceutical Product Pitfalls in Trauma Care

Implementing novel therapies into daily medical practice requires thorough research before regulatory approval and thereafter awareness of cumulative postmarketing medical knowledge. This editorial addresses 2 postmarketing controversies affecting trauma treatment: the retraction of published articles regarding hydroxyethyl starch (HES) and the “back-door” (off-label use) introduction of recombinant factor VIIa (rFVIIa) for intractable hemorrhage in nonhemophiliacs.
Source: Anesthesiology Clinics - Category: Anesthesiology Authors: Source Type: research